Early experience with meropenem- vaborbactam for treatment of carbapenem-resistant enterobacteriaceae infections

Ryan K. Shields; Erin K. McCreary; Rachel V. Marini; Ellen G. Kline; Chelsea E. Jones; Binghua Hao; Liang Chen; Barry N. Kreiswirth; Yohei Doi; Cornelius J. Clancy; M. Hong Nguyen

doi:10.1093/cid/ciz1131

Early experience with meropenem- vaborbactam for treatment of carbapenem-resistant enterobacteriaceae infections

Ryan K. Shields
, Erin K. McCreary
, Rachel V. Marini
, Ellen G. Kline
, Chelsea E. Jones
, Binghua Hao
, Liang Chen
, Barry N. Kreiswirth
, Yohei Doi
, Cornelius J. Clancy
, M. Hong Nguyen

Research output: Contribution to journal › Article › peer-review

88 Citations (Scopus)

Abstract

Twenty patients with carbapenem-resistant Enterobacteriaceae infections were treated with meropenem-vaborbactam. Thirtyday clinical success and survival rates were 65% (13/20) and 90% (18/20), respectively. Thirty-five percent of patients had microbiologic failures within 90 days. One patient developed a recurrent infection due to meropenem-vaborbactam- nonsusceptible, ompK36 porin mutant Klebsiella pneumoniae.

Original language	English
Pages (from-to)	667-671
Number of pages	5
Journal	Clinical Infectious Diseases
Volume	71
Issue number	3
DOIs	https://doi.org/10.1093/cid/ciz1131
Publication status	Published - 01-08-2020
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

All Science Journal Classification (ASJC) codes

Microbiology (medical)
Infectious Diseases

Access to Document

10.1093/cid/ciz1131

Cite this

@article{4fd3c07041154441bfde9a924498c076,

title = "Early experience with meropenem- vaborbactam for treatment of carbapenem-resistant enterobacteriaceae infections",

abstract = "Twenty patients with carbapenem-resistant Enterobacteriaceae infections were treated with meropenem-vaborbactam. Thirtyday clinical success and survival rates were 65\% (13/20) and 90\% (18/20), respectively. Thirty-five percent of patients had microbiologic failures within 90 days. One patient developed a recurrent infection due to meropenem-vaborbactam- nonsusceptible, ompK36 porin mutant Klebsiella pneumoniae.",

keywords = "KPC, Meropenem, P orin, Resistance, Vaborbactam",

author = "Shields, \{Ryan K.\} and McCreary, \{Erin K.\} and Marini, \{Rachel V.\} and Kline, \{Ellen G.\} and Jones, \{Chelsea E.\} and Binghua Hao and Liang Chen and Kreiswirth, \{Barry N.\} and Yohei Doi and Clancy, \{Cornelius J.\} and Nguyen, \{M. Hong\}",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2019.",

year = "2020",

month = aug,

day = "1",

doi = "10.1093/cid/ciz1131",

language = "English",

volume = "71",

pages = "667--671",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "3",

}

TY - JOUR

T1 - Early experience with meropenem- vaborbactam for treatment of carbapenem-resistant enterobacteriaceae infections

AU - Shields, Ryan K.

AU - McCreary, Erin K.

AU - Marini, Rachel V.

AU - Kline, Ellen G.

AU - Jones, Chelsea E.

AU - Hao, Binghua

AU - Chen, Liang

AU - Kreiswirth, Barry N.

AU - Doi, Yohei

AU - Clancy, Cornelius J.

AU - Nguyen, M. Hong

N1 - Publisher Copyright: © The Author(s) 2019.

PY - 2020/8/1

Y1 - 2020/8/1

N2 - Twenty patients with carbapenem-resistant Enterobacteriaceae infections were treated with meropenem-vaborbactam. Thirtyday clinical success and survival rates were 65% (13/20) and 90% (18/20), respectively. Thirty-five percent of patients had microbiologic failures within 90 days. One patient developed a recurrent infection due to meropenem-vaborbactam- nonsusceptible, ompK36 porin mutant Klebsiella pneumoniae.

AB - Twenty patients with carbapenem-resistant Enterobacteriaceae infections were treated with meropenem-vaborbactam. Thirtyday clinical success and survival rates were 65% (13/20) and 90% (18/20), respectively. Thirty-five percent of patients had microbiologic failures within 90 days. One patient developed a recurrent infection due to meropenem-vaborbactam- nonsusceptible, ompK36 porin mutant Klebsiella pneumoniae.

KW - KPC

KW - Meropenem

KW - P orin

KW - Resistance

KW - Vaborbactam

UR - https://www.scopus.com/pages/publications/85088848147

UR - https://www.scopus.com/pages/publications/85088848147#tab=citedBy

U2 - 10.1093/cid/ciz1131

DO - 10.1093/cid/ciz1131

M3 - Article

C2 - 31738396

AN - SCOPUS:85088848147

SN - 1058-4838

VL - 71

SP - 667

EP - 671

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

IS - 3

ER -

Early experience with meropenem- vaborbactam for treatment of carbapenem-resistant enterobacteriaceae infections

Abstract

UN SDGs

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this